Source-grounded facts extracted from Tenon Medical, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Tenon Medical, Inc.: Quorum requirement changed from a majority to not less than 33 1/3% of votes entitled to vote; voting provisions amended so holders of a majority of votes present may require written ballot and inspectors of election (effective 2026-06-10).
“On June 10, 2026, the Board of Directors (the “Board”) of Tenon Medical, Inc. (the “Company’) approved and adopted Amendment No.1 (the “Amendment”) to the Bylaws of the Company (“Bylaws”), effective as of such date.”
Tenon Medical, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“May 21, 2026, Tenon Medical, Inc. (the “Company”) received a written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) dated May 21, 2026, notifying the Company that it is no longer in compliance with the”
Tenon Medical, Inc. reported the first quarter ended March 31, 2026 results: revenue $1.4 million, net income $3.5 million, EPS $0.31 per share.
“PRESS RELEASE OF TENON MEDICAL, INC., DATED MAY 12, 2026 Exhibit 99.1 Tenon® Medical Reports First Quarter 2026 Financial Results ~ First Quarter 2026 Revenue of $1.4 Million, an Increase of Approximately 90% Compared to Prior Year ~ ~ First Quarter Gross Profit of $0.9 Million, an Increase of Approximately 193% Compared to Prior Year ~ ~ Gross Margin”
Tenon Medical, Inc. reported full year 2025 results: revenue $3.9 million, net income net loss was $12.6 million, EPS $1.70 per share.
“Fourth Quarter and Full Year 2025 Financial Results ~ Fourth Quarter 2025 Revenue of $1.5 Million, a 92% Increase Compared to Prior Year ~ ~ Record Full Year 2025 Revenue of $3.9 Million, a 20% Increase compared to Prior Year, Driven by Strong Second Half Momentum ~ ~ Record Full Year 2025 Gross Profit of $2.4 Million, a 38% Increase Compared to Prior Year ~ ~”
Tenon Medical, Inc. reported fourth quarter 2025 results: revenue $1.5 million, net income net loss was $2.8 million, EPS $0.29 per share.
“RELEASE OF TENON MEDICAL, INC., DATED MARCH 19, 2026 Exhibit 99.1 Tenon ® Medical Reports Fourth Quarter and Full Year 2025 Financial Results ~ Fourth Quarter 2025 Revenue of $1.5 Million, a 92% Increase Compared to Prior Year ~ ~ Record Full Year 2025 Revenue of $3.9 Million, a 20% Increase compared to Prior Year, Driven by Strong Second Half Momentum ~ ~ Record”
Tenon Medical, Inc. issued convertible note to certain accredited investors for aggregate gross proceeds of approximately $4.3 million.
“the Company agreed to issue and sell in a private placement an aggregate principal amount of $4.3 million 20% Original Issue Discount Senior Convertible Promissory Notes (the “Notes”) for aggregate gross proceeds of approximately $4.3 million”
Tenon Medical, Inc. entered into Purchase Agreements with certain accredited investors valued at $4.3 million (effective 2026-03-11).
“On March 11, 2026, Tenon Medical, Inc., a Delaware corporation (the “Company”), entered into securities purchase agreements (the “Purchase Agreements”) with certain accredited investors (the “Purchasers”) pursuant to which the Company agreed to issue and sell in a private placement an aggregate principal amount of $4.3 million 20% Original Issue Discount Senior Convertible Promissory Notes (the “Notes”) for aggregate gross proceeds of approximately $4.3 million before deducting fees and expenses of the placement agent.”
Tenon Medical, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A), 5810(b)).
“herein stating that for the 30 consecutive business day period between January 9, 2026 and February 24, 2026, the common stock of the Company had not maintained a minimum closing bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an initial period of 180 calendar days, or until August 24, 2026 (the “Compliance Period”), to regain compliance with the Bid Price Rule. To regain compliance, the closing bid price of the Comp”
Tenon Medical, Inc. issued Pre-Funded Warrants of warrant to certain accredited investors for combined offering price of $1.285 per Share and Warrant.
“(“Pre-Funded Warrants”), and common stock purchase warrants (the “Warrants”), each exercisable for one share of common stock of the Company, at a combined offering price of $1.285 per Share and Warrant to purchase one share of common stock. The Warrants have an exercise price of $1.16 per share and expire 3 years from the date of issuance. The”
Tenon Medical, Inc. issued Warrants to purchase 2,217,904 shares of warrant to certain accredited investors for combined offering price of $1.285 per Share and Warrant.
“(“Pre-Funded Warrants”), and common stock purchase warrants (the “Warrants”), each exercisable for one share of common stock of the Company, at a combined offering price of $1.285 per Share and Warrant to purchase one share of common stock. The Warrants have an exercise price of $1.16 per share and expire 3 years from the date of issuance. The”
Tenon Medical, Inc. issued 2,217,904 shares of common stock to certain accredited investors for combined offering price of $1.285 per Share and Warrant.
“The Company agreed to issue and sell an aggregate of 2,217,904 shares of common stock, par value $0.001 per share (the “Shares”), and/or pre-funded common stock purchase warrants (“Pre-Funded Warrants”), and common stock purchase warrants (the “Warrants”), each exercisable for one share of common stock of the Company, at a combined offering price of $1.285 per Share and Warrant to purchase one share of common stock.”
Tenon Medical, Inc. completed an acquisition involving SiVantage, Inc. (closed 2025-08-01).
“On August 1, 2025 (the “SI Closing Date”), Tenon Medical, Inc. (the “Company”), entered into an asset purchase agreement (the “SI APA”) by and between the Company and SiVantage, Inc., a Delaware corporation (“SI”), pursuant to which the Company acquired substantially all of the assets of SI (the “SImmetry Business”)”
Kevin Williamson was appointed as Chief Financial Officer at Tenon Medical, Inc..
“On August 20, 2024, Tenon Medical, Inc. (the “Company”) entered into an offer letter (the “Letter”) with Kevin Williamson pursuant to which Mr. Williamson was appointed as Chief Financial Officer of the Company, effective as of September 3, 2024.”
Steven Van Dick resigned as Chief Financial Officer at Tenon Medical, Inc..
“Steven Van Dick informed Tenon Medical, Inc. (the “Company”) of his decision to retire and as a result, is resigning from his positions as Executive Vice President, Finance and Administration, Chief Financial Officer and Assistant Secretary effective as of July 31, 2024.”
Tenon Medical, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“ule 5550(a)(2) (the “Bid Price Rule”). Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an initial”
Kristine Jacques was appointed as Director at Tenon Medical, Inc..
“On March 25, 2024, the Board of Directors (the “Board”) of Tenon Medical, Inc. (the “Company”) appointed Kristine Jacques as a member of the Board effective as of March 25, 2024.”
Tenon Medical, Inc. reported the fourth quarter and full year ended December 31, 2023 results: revenue $808,000 in the fourth quarter of 2023.
“On March 12, 2024, Tenon Medical, Inc. (the “Company”) issued a press release announcing its earnings for the fourth quarter ended December 31, 2023 and the fiscal year ended December 31, 2023.”
Tenon Medical, Inc. entered into Securities Purchase Agreement with certain investors valued at $2,605,000 (effective 2024-02-20).
“On February 20, 2024 (the “Closing Date”), Tenon Medical, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain investors (the “Investors”), pursuant to which the Company agreed to sell, issue and deliver to the Investors, in a private placement offering (the “Offering”), a total of 172,239 shares of the Company’s Series A Preferred Stock (the “Series A Preferred Stock”) and warrants (the “Warrants”) to purchase 258,374 shares of common stock, par value $0.001 per share, of the Company (“Common Stock”) at an exercise price equal to $1.2705 per share for an aggregate offering price of $2,605,000.”
Tenon Medical, Inc. shareholders approved Amendment to the Second Amended and Restated Certificate of Incorporation to vest the Board with authority to issue preferred stock at the 2024-01-30 meeting.
“For Against Abstain 1,243,383 73,920 21,473”
Tenon Medical, Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605, 5605(b)(1)(A)).
“January 4, 2024, Tenon Medical, Inc. (the “Company”) received a written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) dated January 4, 2024, indicating that, as a result of Frank Fischer’s resignation from the Board of Directors of the Company (“Board”), audit committee of the Board (the “Audit Committee”) and compensation committee of the Board (the “Compensation Committee”), effective November 30, 2023, that the Company is not currently in compliance with Nasdaq Listing Rule 5605, which requires that (i) a majority of the Board be comprised of independent directors, (ii)”
Tenon Medical, Inc. shareholders rejected To approve an amendment to the Certificate of Incorporation to vest the Board with authority to issue preferred stock at the 2024-01-08 meeting.
“At the Meeting, the stockholders did not approve Proposal 2. The votes on Proposal 2 were cast as set forth below: Proposal No. 2 – To consider and vote on a proposal to approve an amendment to the Company’s Second Amended and Restated Certificate of Incorporation”
Tenon Medical, Inc. shareholders approved To consider and vote on the proposal to adjourn the Special Meeting, if necessary or appropriate, to solicit additional proxies. at the 2023-12-21 meeting.
“Proposal No. 4 – To consider and vote on the proposal to adjourn the Special Meeting, if necessary or appropriate, to solicit additional proxies. For Against Abstain 1,356,229 127,140 10,132”
Tenon Medical, Inc. shareholders approved To consider and vote on a proposal to approve an amendment (the "Reverse Stock Split Amendment") to the Certificate of Incorporation to provide for a reverse stock split (the "Reverse Stock Split") of the Common Stock, that will be at a ratio ranging from one for two (1:2) to one for fifty (1:50) (t at the 2023-12-21 meeting.
“Proposal No. 3 – To consider and vote on a proposal to approve an amendment (the "Reverse Stock Split Amendment") to the Certificate of Incorporation to provide for a reverse stock split (the "Reverse Stock Split") of the Common Stock, that will be at a ratio ranging from one for two (1:2) to one for fifty (1:50) (the "Split Ratio Range"), the final determination of which shall be determined by the Board; and For Against Abstain 1,378,827 114,415 5,261”
Tenon Medical, Inc. shareholders rejected To consider and vote on a proposal to approve an amendment (the "Blank Check Preferred Amendment") to the Company's Second Amended and Restated Certificate of Incorporation, as amended (the "Certificate of Incorporation"), to expressly vest in the Board of Directors of the Company (the "Board") the at the 2023-12-21 meeting.
“Proposal No. 2 – To consider and vote on a proposal to approve an amendment (the "Blank Check Preferred Amendment") to the Company's Second Amended and Restated Certificate of Incorporation, as amended (the "Certificate of Incorporation"), to expressly vest in the Board of Directors of the Company (the "Board") the authority to issue the preferred stock with powers, designations, preferences and relative, participating, optional or other rights, if any, or the qualifications, limitations or restrictions thereof as the Board; For Against Abstain 903,573 65,526 16,687”
Tenon Medical, Inc. shareholders approved To consider and vote on a proposal to approve, for purposes of Nasdaq Listing Rule 5635(d) and Nasdaq Listing Rule 5635(b), the issuance of the maximum number of shares of our common stock issuable under the terms of Series A Preferred Stock and Warrants to be issued by the Company to investors at the 2023-12-21 meeting.
“Proposal No. 1 – To consider and vote on a proposal to approve, for purposes of Nasdaq Listing Rule 5635(d) and Nasdaq Listing Rule 5635(b), the issuance of the maximum number of shares of our common stock issuable under the terms of Series A Preferred Stock and Warrants to be issued by the Company to investors; For Against Abstain 938,808 35,310 11,668”
Frank Fischer resigned as Director at Tenon Medical, Inc..
“On November 30, 2023, Frank Fischer informed Tenon Medical, Inc. (the “Company”) of his resignation as a member of the Company’s Board of Directors (“Board”), which was immediately effective.”
Tenon Medical, Inc. entered into Securities Purchase Agreements with certain investors valued at $1,250,000 (effective 2023-11-21).
“On November 21, 2023, Tenon Medical, Inc. (the “Company”) entered into Securities Purchase Agreements (the “Purchase Agreements”) with certain investors (the “Investors”), pursuant to which the Company agreed to sell, issue and deliver to the Investors, in a private placement offering (the “Offering”), a total of $1,250,000 in secured notes (the “Notes”) and warrants (the “Warrants”)”
Tenon Medical, Inc.: Certificate of Amendment to effect a 1-for-10 reverse stock split (effective 2023-11-02).
“filed on November 1, 2023 a Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation, of the Company with the Secretary of State of the State of Delaware (the “Certificate of Amendment”) that provides for a 1-for-10 reverse stock split (the “Split”) of its shares of common stock, par value $0.001 per share (the “Common Stock”) that became effective at 12:01 a.m. on November 2, 2023.”
Tenon Medical, Inc. entered into Purchase Agreement with Lincoln Park Capital Fund, LLC valued at up to $10 million of shares of common stock (effective 2023-07-24).
“On July 24, 2023, Tenon Medical, Inc. (the "Company") entered into a purchase agreement ("Purchase Agreement") with Lincoln Park Capital Fund, LLC ("Lincoln Park"), under which, subject to specified terms and conditions, the Company may sell to Lincoln Park up to $10 million of shares of common stock from time to time during the term of the Purchase Agreement.”
Tenon Medical, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“ule 5550(a)(2) (the “Bid Price Rule”). Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an initial”
Tenon Medical, Inc. entered into Placement Agency Agreement with Maxim Group LLC (effective 2023-06-14).
“The Company also entered into a Placement Agency Agreement with the Placement Agent (the “Placement Agency Agreement”) on June 14, 2023.”
Tenon Medical, Inc. entered into Securities Purchase Agreement with two investors valued at $5.6 million (effective 2023-06-14).
“On June 14, 2023, Tenon Medical, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with two investors, pursuant to which the Company agreed to sell, issue and deliver to such investors a total of 747,600 units ( “Units"), with each Unit consisting of (i) one share of common stock of the Company (the “Common Stock"), par value $0.001 per share, and (ii) two warrants, each warrant to purchase one share of Common Stock at an exercise price equal to $0.56 per share of Common Stock (the “Warrants").”
Tenon Medical, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“May 17, 2023, Tenon Medical, Inc. (the “Company”) received a written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) dated May 17, 2023, notifying the Company that it is no longer in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires listed companies to maintain stockholders’ equity of at least $2,500,000. In the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023, the Company reported stockholders’ equity of $2,474,000, which is below the mi”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.